Concept of a point of care test to detect new oral anticoagulants in urine samples

Thrombosis Journal

Roland Krämer¹  Christel Weiss³  Shanshan Du²  Sandra Krämer²  Job Harenberg² 

[1] Inorganic Chemistry Institute, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany;Clinical Pharmacology, Medical Faculty of Medicine Mannheim, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany;Biometry and Statistics, Medical Faculty of Medicine Mannheim, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany

关键词: Compliance;    Monitoring;    Coagulation assay;    Urine;    Anticoagulation;    Renal function;    Apixaban;    Rivaroxaban;    Dabigatran;    Oral anticoagulant;   

Others  :  838535
DOI  :  10.1186/1477-9560-11-15

 received in 2013-04-04, accepted in 2013-07-16,  发布年份 2013

【 摘 要 】

New oral anticoagulants (NOAC) are approved for several indications for prophylaxis and treatment of venous thromboembolism and for prevention of embolism in atrial fibrillation at fixed daily doses without need of laboratory guided dose adjustment. Due to their low molecular weight of about 500 to 600 Dalton and their hydrophilicity free anticoagulant is excreted immediately through glomerular filtration into the urine. Impairment of renal function may increase the plasma concentration of the anticoagulants and lowered creatinine clearance is a declared contraindication. In contrast to the initial aim of development the anticoagulant effect is required to be determined in special clinical situations. Several specific and non-specific assays using plasma samples are currently undergoing standardization. As all NOACs are excreted into the urine, specific assays were developed for this matrix to determine them quantitatively of qualitatively. Urine samples can be easily and repetitively obtained avoiding problems and risks associated with blood sampling. The qualitative assay can be performed as a point of care test (POC) also by the patient by judging the different colours for the absence or presence of the drugs with the naked eye. The test is rapid (results available within 15 min), sensitive, specific and accurate and does not require a purified NOAC as control. The tests may be a tool for clinicians who need to know for treatment decisions if a NOAC is on board or not. As the tests are specific for oral direct thrombin inhibitors and for oral direct factor Xa inhibitors, the indication does not interfere with other qualitative POC test in development using clotting systems. The test may be indicated for patients at acute hospitalization, before surgery or central nervous system puncture anaesthesia, if fibrinolytic therapy is indicated, acute deterioration of renal function, and for control of adherence to therapy.

【 授权许可】

   
2013 Harenberg et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr: Prevention of VTE in orthopedic surgery patients. Chest 2012, 141:e278S-e325S.
• [2]Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM: Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010, 104:1106-1115.
• [3]Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crother M: Treatment and prevention of heparin-induced thrombocytopenia. Chest 2012, 141:e495S-e530S.
• [4]Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G: Pharmacology and management of the vitamin K antagonists. Chest 2008, 133:160S-198S.
• [5]Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY: Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010, 123:638-645. e4
• [6]van den Besselaar AM, Péquériaux NC, Ebben M, van der Feest J, de Jong K, Ganzeboom MB, van Ooijen J, Postema F, Witteveen E, van der Meer FJ: Point-of-care monitoring of vitamin k-antagonists: validation of coaguchek xs test strips with international standard thromboplastin. J Clin Pathol 2012, 65:1031-1035.
• [7]Hur M, Kim H, Park CM, La Gioia A, Choi SG, Choi JH, Moon HW, Yun YM: Comparison of international normalized ratio measurement between CoaguChek XS plus and STA-R coagulation analyzers. Biomed Res Int 2013.
• [8]Garcia-Alamino JM, Ward AM, Alonso-Coello P, Perera R, Bankhead C, Fitzmaurice D, Heneghan CJ: Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2010.
• [9]Heneghan C, Ward A, Perera R: Self-monitoring trialist collaboration: self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012, 379:322-334.
• [10]Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, Lufft V, Wand DD, Philipp T, Bruck H: Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010, 70:703-712.
• [11]Favaloro EJ, Lippi G, Koutts J: Laboratory testing of anticoagulants: the present and the future. Pathology 2011, 43:682-692.
• [12]Favaloro EJ, Lippi G: Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against? Clin Chem Lab Med 2011, 49:755-757.
• [13]Szelke H, Schübel S, Harenberg J, Krämer R: A fluorescent probe for the quantification of heparin in clinical samples with minimal matrix interference. Chem Commun 2010, 46:1667-1669.
• [14]Stehle G, Wunder A, Sinn H, Schrenk HH, Harenberg J, Malsch R, Maier-Borst W, Heene DL: Pharmacokinetic properties of LMW-heparin-tyramine fractions with high or low affinity to antithrombin III in the rat. Semin Thromb Hemost 1997, 23:31-37.
• [15]Malsch R, Timmermann A, Harenberg J: Capillary electrophoresis of r-hirudin and a polyethylene glycol derivative of r-hirudin (PEG-hirudin). Semin Thromb Hemost 1997, 23:39-43.
• [16]De Vries JX, Simon M, Zimmermann R, Harenberg J: Identification of phenprocoumon metabolites in human urine by high-performance liquid chromatography and gas chromatography–mass spectrometry. J Chromatogr 1985, 338:325-334.
• [17]Harenberg J, Stehle G, Waibel S, Hermann HJ, Eisenhut M, Zimmermann R: Disposition of human fibrinopeptide A in normal and nephrectomized rabbits. Thromb Res 1983, 32:1-13.
• [18]Harenberg J, Kraemer R: Measurement of the new anticoagulants. Thromb Res 2012, 129(Suppl 1):S106-S113.
• [19]Harenberg J, Du S, Krämer S, Giese C, Schulze A, Weiss C, Krämer R: Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples. Semin Thromb Hemost 2013, 39:66-71.
• [20]Harenberg J, Kraemer R: Direct thrombin inhibitors. 2012. International Patent No. PCT/EP2012/002540
• [21]Harenberg J, Kraemer R: Direct factor Xa inhibitors. 2011. International Patent No. PCT/EP2011/005586
• [22]Mahler C, Hermann K, Horne R, Ludt S, Haefeli WE, Szecsenyi J: Assessing reported adherence to pharmacological treatment recommendations. J Eval Clin Pract 2010, 16:574-579.
• [23]Attema-de Jonge ME, Peeters SY, Franssen EJ: Performance of three point of-care urinalysis test devices for drugs of abuse and therapeutic drugs applied in the emergency department. J Emerg Med 2012, 42:682-691.
• [24]Cervinski MA, Lockwood CM, Ferguson AM, Odem RR, Stenman UH, Alfthan H: Qualitative point-of-care and over-the-counter urine hCG devices differentially detect the hCG variants of early pregnancy. Clin Chim Acta 2009, 406:81-85.